Cargando…

Advances in Targeted Therapy for the Treatment of Cervical Cancer

Cervical cancer is an international public health crisis, affecting several hundred thousand women annually. While not universally protective due to other risk factors, many such cases are preventable with vaccination against high-risk serotypes of the human papilloma virus (HPV 6, 11, 16, 18, 31, 3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watkins, Dean E., Craig, Daniel J., Vellani, Shahnaz D., Hegazi, Ahmad, Fredrickson, Kaylee J., Walter, Adam, Stanbery, Laura, Nemunaitis, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531664/ https://www.ncbi.nlm.nih.gov/pubmed/37762931 http://dx.doi.org/10.3390/jcm12185992

Ejemplares similares

Systemic benefit of radiation therapy via abscopal effect
por: Craig, Daniel J., et al.
Publicado: (2022)

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer
por: Nemunaitis, John, et al.
Publicado: (2023)

BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
por: Morand, Susan, et al.
Publicado: (2020)

HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report
por: Fortman, Dylan, et al.
Publicado: (2019)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
por: Nemunaitis, John, et al.
Publicado: (2020)

Ovarian Cancer Immunotherapy and Personalized Medicine
por: Morand, Susan, et al.
Publicado: (2021)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
por: Oh, Johnathan, et al.
Publicado: (2020)

Resident Memory T Cells and Their Effect on Cancer
por: Craig, Daniel J., et al.
Publicado: (2020)

Adenomatous polyposis coli in cancer and therapeutic implications
por: Noe, Olivia, et al.
Publicado: (2021)

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
por: Barve, Minal, et al.
Publicado: (2022)

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2022)

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
por: Rocconi, Rodney P., et al.
Publicado: (2021)

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2023)

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
por: Barve, Vedin, et al.
Publicado: (2021)

Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
por: Sliheet, Elyssa, et al.
Publicado: (2021)

NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
por: Devanaboyina, Monika, et al.
Publicado: (2022)

Current Ovarian Cancer Maintenance Strategies and Promising New Developments
por: Gogineni, Vinaya, et al.
Publicado: (2021)

Homologous recombination proficiency in ovarian and breast cancer patients
por: Creeden, Justin Fortune, et al.
Publicado: (2021)

Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease
por: Simmons, Olivia, et al.
Publicado: (2012)

Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics
por: Vorhies, John S, et al.
Publicado: (2007)

Harnessing the immune response to target tumors
por: Manning, Luisa, et al.
Publicado: (2017)

Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
por: Eskander, Ramez N., et al.
Publicado: (2014)

1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2
por: Jay, C., et al.
Publicado: (2020)

Assay development and high-throughput screening for small molecule inhibitors of a Vibrio cholerae stress response pathway
por: Stanbery, Laura, et al.
Publicado: (2017)

Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey
por: Richardson, Michael T., et al.
Publicado: (2023)

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
por: Nemunaitis, John, et al.
Publicado: (2012)

Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
por: Anderson, Peter, et al.
Publicado: (2023)

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
por: Alqahtani, Ali, et al.
Publicado: (2019)

Steps solidifying a role for SEPT9 in breast cancer suggest that greater strides are needed
por: Stanbery, Laura, et al.
Publicado: (2012)

Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors
por: Vellani, Shahnaz D., et al.
Publicado: (2023)

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
por: Bramhall, S R, et al.
Publicado: (2002)

Targeted therapy in cervical cancer
por: Vora, Chakor, et al.
Publicado: (2019)

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
por: Nemunaitis, John, et al.
Publicado: (2013)

Advances in targeted therapy for malignant lymphoma
por: Wang, Li, et al.
Publicado: (2020)

Medical Advances in Hepatitis D Therapy: Molecular Targets
por: Vogt, Amelie, et al.
Publicado: (2022)

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours
por: Faessel, Hélène, et al.
Publicado: (2019)

Editorial: Targeted therapy in advanced thyroid cancer
por: Boucai, Laura
Publicado: (2022)

Voice Your Values, Tailored Advance Care Planning in Persons Living With Mild Dementia: A Feasibility Study
por: Vellani, Shirin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_if5a4hd6nq7rfc14771rjjm7ao